Trial reportNature medicine2022
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06894784 (Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial.Journal of diabetes science and technology · 2023Trial
- Trial
- Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.Diabetes care · 2023 · on this mapTrial
- Metabolic Responses to Exercise and Nutritional Strategies in Type 1 Diabetes Using Automated Insulin Delivery Systems: A Narrative Review.Metabolites · 2026Review
- Sensor-based digital health technologies to capture endpoints in recent clinical trials: a scoping review.NPJ digital medicine · 2026Article
- Time in LDL cholesterol target range and major adverse cardiovascular events risk: A pooled analysis of two cohorts.American journal of preventive cardiology · 2025Article
- Closed-Loop Bioelectronic Artificial Pancreas Patch for Continuous Monitoring and Regulation of Blood Glucose in Diabetic Rats and Pigs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Early Stages of Automated Insulin Delivery.Diabetes technology & therapeutics · 2025Review
- Early Stages of Automated Insulin Delivery.Journal of diabetes science and technology · 2025Review
- New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.Genes & diseases · 2024Review
- Higher fibre and lower carbohydrate intake are associated with favourable CGM metrics in a cross-sectional cohort of 470 individuals with type 1 diabetes.Diabetologia · 2024Article
- Review
- Elevated urinary albumin predicts increased time in range after initiation of SGLT2 inhibitors in individuals with type 1 diabetes on sensor-augmented pump therapy.Diabetology international · 2024Article
- The emergence of obesity in type 1 diabetes.International journal of obesity (2005) · 2024Review
- Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.International journal of molecular sciences · 2024Review
- The Effect of Sodium-Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Mitigating iftar-related glycemic excursions in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed loop system: a randomized clinical trial for adjunctive oral vildagliptin therapy during Ramadan fasting.Diabetology & metabolic syndrome · 2023Article
- New therapies towards a better glycemic control in youths with type 1 diabetes.Pharmacological research · 2023Review
- The changing landscape of automated insulin delivery in the management of type 1 diabetes.Endocrine connections · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
There is a need to optimize closed-loop automated insulin delivery in type 1 diabetes. We assessed the glycemic efficacy and safety of empagliflozin 25 mg d
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.